SALEM, N.H., March 31 /PRNewswire/ -- AgaMatrix, Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions.

- Study Presented at 69th Annual ADA Scientific Sessions Examined Efficacy and Safety of Basal-Prandial Treatment with Lantus(R) and Apidra(R) - NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S.

BRIDGEWATER, N.J., April 20 /PRNewswire/ -- Sanofi-aventis U.S. announced today that Apidra(R) SoloSTAR(R) (insulin glulisine [rDNA origin] injection), a prefilled disposable pen containing the rapid-acting insulin analog Apidra(R), is now available in the United States.

- Apidra(R) SoloSTAR(R) is a Convenient Insulin Delivery Device to Help Patients with Diabetes Improve Glycemic Control BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S.

French pharmaceutical company Sanofi-Aventis has announced that the FDA has approved Apidra to improve glycemic control in children with diabetes mellitus.